Zhejiang Medicine repurchase reaches 1% of total share capital

Zhejiang Medicine Co., Ltd. (SSE:600216) announced that its share repurchase program has reached 1% of the company's total share capital as of June 30, 2025. The company has repurchased 9,619,400 shares through centralized bidding, accounting for 1.00% of the total share capital. The repurchase price ranged from CNY 13.31 to CNY 15.10 per share, with a total expenditure of CNY 136,538,850 (excluding transaction costs). The repurchase program, approved on April 14, 2025, aims to enhance shareholder value and will be used for employee stock ownership plans or equity incentives. The repurchase period extends until April 14, 2026, with a total repurchase amount between CNY 100 million and CNY 200 million. The company stated it will continue to implement the repurchase plan in accordance with market conditions and regulatory requirements.